MedPath

Long-term Outcomes of Open Versus Laparoscopic Distal Gastrectomy for T4a Gastric Cancer

Completed
Conditions
Gastric Cancer
Interventions
Procedure: Laparoscopic distal gastrectomy
Registration Number
NCT05493358
Lead Sponsor
University Medical Center Ho Chi Minh City (UMC)
Brief Summary

There are more than 75% of patients with gastric cancer who are diagnosed in advanced stage in Vietnam, most of cases in T4a. The purpose of this study was to compare short- and long- term outcomes of open and laparoscopic distal gastrectomy for gastric adenocarcinoma in surgical T4A stage.

Detailed Description

Gastric cancer is one of the most common cancers in Vietnam . Despite recent advances in multimodality treatment and targeted therapy, surgery remains the first option of treament for this disease. For resectable gastric cancer, complete removal of macroscopic and microscopic lesions and/or combined resections and also regional or extended lymphadenectomy should represent worldwide now.

Laparoscopic gastrectomy for locally advanced gastric cancer AGC have commonly used for treatment of AGC, especially in Japan, Korea and China. However, the real role of laparoscop for treament of (AGC) is still controversial in term of technical feasibility, safety and oncologic aspect for T4a stage.

Paragastric inflammatory strands may occur in T4a tumor so that laparoscopic technique is difficult to radically perform. Peritoneal seeding of malignant cells, intra- and postoperative complications, trocarts metastasis may risk during procedures. Despite, some studies have demonstrated the safety and the short-term benefits of LG for T4a gastric cancer, the number of these studies and sample sizes have been still inadequate to give good evidence for applying it. and long-term oncologic outcomes There are more than 75% of patients with gastric cancer who are diagnosed in advanced stage in Vietnam, most of cases in T4a. The purpose of this study was to compare short- and long- term outcomes of open and laparoscopic distal gastrectomy for gastric adenocarcinoma in surgical T4A stage.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
472
Inclusion Criteria
  • patients with histologically confirmed adenocarcinoma of the stomach, surgical staging of sT4aN0-3M0 according to the 7th edition of the American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) staging system
Exclusion Criteria
  • intraoperatively detected bulky lymph nodes
  • inadequate lymphadenectomy (D0, D1, D1+)
  • macroscopic residual tumor (R2)
  • an American Society of Anaesthesiology (ASA) score of > IV
  • concurrent cancer or history of previous other cancers
  • previous gastrectomy
  • neoadjuvant chemotherapy
  • complications such as bleeding or perforation required emergency gastrectomy.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Laparoscopic distal gastrectomyLaparoscopic distal gastrectomy5 trocar were used. The gastrocolic ligament was divided along the border of the transverse colon. ligating the left gastroepiploic vessels to remove group 4sb. The right gastroepiploic vein was divided and the right gastroepiploic and the inferior pyloric artery were vascularized and cut at their origin from the gastroduodenal artery, just above the pancreatic head, to dissect group 6. The dissection was continued along the hepatoduodenal ligament to removed group 5 and group 12a and along the common hepatic artery to remove group 8a and along the celiac axis to remove group 9. The left gastric vein was prepared and separately divided and then the left gastric artery was vascularized to remove group 7. The dissection was continued upward along the proximal branches of splenic vessels to remove group 11p and along the lesser curvature to remove group 1,3. As a general rule, Billroth I, Billroth II or Roux en Y method was used for gastric reconstruction.
Primary Outcome Measures
NameTimeMethod
5 year disease-free survival by Kaplan Mayer5 year after surgery

The percentage of people in this study who are alive without recurrence/metastasis five years after surgery.

5 year overall survival by Kaplan Mayer5 year after surgery

The percentage of people in this study who are alive five years after surgery.

Secondary Outcome Measures
NameTimeMethod
3 year overall survival by Kaplan Mayer3 year after surgery

The percentage of people in this study who are alive one years after surgery.

1 year overall survival by Kaplan Mayer1 year after surgery

The percentage of people in this study who are alive one years after surgery.

1 year disease-free survival by Kaplan Mayer1 year after surgery

The percentage of people in this study who are alive without recurrence/metastasis one years after surgery.

3 year disease-free survival by Kaplan Mayer3 year after surgery

The percentage of people in this study who are alive without recurrence/metastasis one years after surgery.

operative morbidity30 days after surgery

The overall rate of postoperative complications

operative timeintraoperative

The duration of a surgical procedure in minutes.

operative blood lossintraoperative

The amount of blood lost during procedure

time to flatus30 days after surgery or until mortality ]

Number of days from date of surgery until date of flatus

Postoperative hospital length of stay30 days after surgery or until mortality

Number of days from date of surgery until date of discharge or mortality

The percentage of complications with Clavien-Dindo30 days after surgery

The percentage of complication grade by Clavien-Dindo classification

The percentage of pattern of recurrence/metastasis5 year after surgery

The percentage of pattern of recurrence/metastasis during follow up period

Trial Locations

Locations (1)

University Medical Center Ho Chi Minh City

🇻🇳

Ho Chi Minh City, Vietnam

© Copyright 2025. All Rights Reserved by MedPath